Related Experiment Videos
Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives
L J Feldman1, O Tahlil, P G Steg
1Department of Cardiology, Hôpital Bichat, Paris, France.
Insights
Gene therapy shows promise for treating restenosis after angioplasty by inhibiting smooth muscle cell proliferation. Adenoviral vectors effectively deliver therapeutic genes, but technical challenges need resolution for clinical application.
Area of Science:
- Interventional Cardiology
- Gene Therapy
- Vascular Biology
Background:
- Restenosis, characterized by arterial renarrowing post-angioplasty, is a major clinical challenge.
- Intimal hyperplasia, driven by smooth muscle cell proliferation, is a key contributor to restenosis.
- Gene therapy offers a potential strategy to target smooth muscle cell proliferation.
Purpose of the Study:
- To evaluate the efficacy of gene therapy in inhibiting smooth muscle cell proliferation and intimal hyperplasia.
- To assess the role of adenoviral vectors in in vivo arterial gene transfer for restenosis treatment.
Main Methods:
- Utilized adenoviral vectors for in vivo arterial gene transfer.
- Delivered therapeutic genes encoding cytotoxic (herpes virus thymidine kinase) and cytostatic (Rb, Gax, endothelial nitric oxide synthase) products.
- Investigated the inhibition of smooth muscle cell proliferation and intimal hyperplasia.
Main Results:
- Therapeutic genes encoding cytotoxic or cytostatic products demonstrated success in inhibiting smooth muscle cell proliferation.
- Adenoviral vectors proved efficient for in vivo arterial gene transfer.
- Successful inhibition of intimal hyperplasia was observed.
Conclusions:
- Gene therapy, particularly using adenoviral vectors, is a promising approach for managing restenosis.
- Further research is needed to address technical issues such as vector toxicity and transduction efficiency in atherosclerotic arteries.
- Clinical application of gene therapy for restenosis requires overcoming current limitations.
Abstract:
Restenosis remains the main limitation of interventional cardiology. Restenosis occurs when angioplasty-induced intimal hyperplasia as well as arterial remodelling result in flow-limiting renarrowing of the arterial lumen at the angioplasty site. Intimal hyperplasia is an important candidate for gene therapy since it is related to smooth muscle cell proliferation, which is an inviting target for molecular antiproliferative strategies. To date, adenoviral vectors are, by far, the most efficient vectors to perform in vivo arterial gene transfer. These vectors, as well as others, have been recently used to demonstrate that therapeutic genes encoding cytotoxic (herpes virus thymidine kinase) or cytostatic (hypophosphorylatable Rb, Gax, endothelial nitric oxide synthase) products successfully inhibit smooth muscle cell proliferation and related intimal hyperplasia. Despite substantial progress, major technical issues, including the toxicity of first-generation adenoviral vectors, inefficient transduction of atherosclerotic arteries, and the risk of extra-arterial transfection remain to be addressed before gene therapy is applied to clinical restenosis.